Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
12
CRVS Quote, Financials, Valuation and Earnings
Last price:
$5.04
Seasonality move
:
-9.57%
Day range:
$4.73 - $5.34
52-week range:
$1.30 - $10.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
25.89x
Volume:
2.6M
Avg. volume:
1.4M
1-year change:
220.51%
Market cap:
$321.3M
Revenue:
--
EPS (TTM):
-$0.92
Analysts' Opinion
-
Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.75, Corvus Pharmaceuticals has an estimated upside of 215% from its current price of $5.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing -140% downside risk from its current price of $5.00.
Fair Value
-
According to the consensus of 5 analysts, Corvus Pharmaceuticals has 215% upside to fair value with a price target of $15.75 per share.
CRVS vs. S&P 500
-
Over the past 5 trading days, Corvus Pharmaceuticals has underperformed the S&P 500 by -30.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Corvus Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corvus Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Corvus Pharmaceuticals reported revenues of --.
Earnings Growth
-
Corvus Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Corvus Pharmaceuticals reported earnings per share of -$0.60.
Enterprise value:
279.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$33.7M | -$23.4M | -$25.1M | -$5.6M | -$7.3M | |
| EBITDA | -$31.2M | -$23.2M | -$25M | -$5.5M | -$7.2M | |
| Diluted EPS | -$0.88 | -$0.64 | -$0.92 | -$0.12 | -$0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $52.5M | $78.8M | $51.3M | $33.1M | $42.9M | |
| Total Assets | $55.9M | $119.3M | $80.3M | $51.9M | $58.8M | |
| Current Liabilities | $12M | $11.3M | $14M | $7.3M | $46.4M | |
| Total Liabilities | $13.5M | $14.2M | $15.7M | $7.7M | $46.4M | |
| Total Equity | $42.4M | $105.1M | $64.7M | $44.3M | $12.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.3M | -$26.3M | -$22.1M | -$5.4M | -$6.3M | |
| Cash From Investing | -$21.4M | $14M | -$23.7M | $17.5M | -$3.9M | |
| Cash From Financing | $18K | $7.9M | $30.4M | $335K | $50K | |
| Free Cash Flow | -$26.6M | -$26.3M | -$22.1M | -$5.4M | -$6.3M | |
CRVS
Sector
Market Cap
$321.3M
$44.6M
Price % of 52-Week High
50%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
220.51%
-29.09%
Beta (5-Year)
1.049
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$6.58
200-day SMA
Buy
Level
$4.09
Bollinger Bands (100)
Sell
Level
4.21 - 8.29
Chaikin Money Flow
Buy
Level
15.2M
20-day SMA
Sell
Level
$7.75
Relative Strength Index (RSI14)
Sell
Level
28.05
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-73.9415
50-day SMA
Sell
Level
$8.03
MACD (12, 26)
Sell
Level
-0.71
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
455.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Stock Forecast FAQ
In the current month, CRVS has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRVS average analyst price target in the past 3 months is $15.75.
-
Where Will Corvus Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corvus Pharmaceuticals share price will rise to $15.75 per share over the next 12 months.
-
What Do Analysts Say About Corvus Pharmaceuticals?
Analysts are divided on their view about Corvus Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corvus Pharmaceuticals is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Corvus Pharmaceuticals's Price Target?
The price target for Corvus Pharmaceuticals over the next 1-year time period is forecast to be $15.75 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corvus Pharmaceuticals is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRVS?
You can purchase shares of Corvus Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corvus Pharmaceuticals shares.
-
What Is The Corvus Pharmaceuticals Share Price Today?
Corvus Pharmaceuticals was last trading at $5.04 per share. This represents the most recent stock quote for Corvus Pharmaceuticals. Yesterday, Corvus Pharmaceuticals closed at $5.00 per share.
-
How To Buy Corvus Pharmaceuticals Stock Online?
In order to purchase Corvus Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
